Guidelines

Renal denervation proceeds as U.S. trial’s flaws emerge


 

EXPERT ANALYSIS FROM EUROPCR 2014

The global divide in renal denervation use

The inability of the SYMPLICITY HTN-3 trial to prove the treatment’s efficacy has further divided use of renal denervation by geography. The technology remains unapproved for U.S. use, and will remain that way until another large, sham-controlled trial finishes and shows a clear benefit for BP reduction. In contrast, the procedure’s use in Europe seems on track to continue and grow further, although European thought leaders urge caution and further research to identify the best denervation techniques and optimal patients.

European leaders such as Dr. Mahfoud and Dr. Schmieder also see great promise in using renal denervation for other types of patients, such as those with heart failure or arrhythmias. Just one example of the wide-ranging effects examined for renal denervation was a report Dr. Mahfoud cited published earlier this year that focused on changes in left ventricular mass in 55 patients with resistant hypertension who underwent renal denervation. The results collected by Dr. Mahfoud and his associates showed that even when patients experienced little or no change in their systolic BP they often had substantial reductions in left ventricular mass (Eur. Heart J. 2014 March 6 [doi:10.1093/eurheartj/ehu093]).

"Reducing systolic blood pressure by 10 mm Hg [in patients with severe, drug-resistant hypertension] would have a massive impact, so renal denervation remains an important tool for potentially benefiting patients with uncontrolled hypertension," Dr. Wijns, codirector of the Cardiovascular Center in Aalst, Belgium, said in an interview.

But the renal denervation tool that is increasingly seen as important by the cardiovascular disease leadership in Europe will remain beyond the reach of U.S. physicians for some time to come.

The SYMPLICITY HTN-3 trial and the Global SYMPLICITY Registry were sponsored by Medtronic, which markets the Symplicity catheter. All of the sources for this article have received speaker fees, consulting fees, and/or research grants from Medtronic and numerous other medical device, drug, or biotechnology companies.

mzoler@frontinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

Statin users ate more, gained more weight during 1999-2010
MDedge Internal Medicine
Salt targets could reduce cardiovascular disease burden and health expenditures
MDedge Internal Medicine
Significant improvements in adherence, blood pressure, and LDL cholesterol with polypill
MDedge Internal Medicine
Empagliflozin improves glycemia, blood pressure in type 2 diabetes study
MDedge Internal Medicine
Registry renal denervation skews from resistant hypertension
MDedge Internal Medicine
FDA approves blood test for membranous glomerulonephritis
MDedge Internal Medicine
VIDEO: In SYMPLICITY, operator inexperience produced incomplete ablations
MDedge Internal Medicine
Poor cardiovascular health predicted cognitive impairment
MDedge Internal Medicine
Antihypertensive benefit of CPAP holds up in real-world settings
MDedge Internal Medicine
Olmesartan can cause celiac disease mimicker
MDedge Internal Medicine

Related Articles